美国
证券交易所
华盛顿特区20549
表格
公司当前报告
根据《证券交易法》第13或15(d)条款 执行
1934年证券交易法
报告日期
(所报告的最早事件日期):
（按其章程规定的确切名称）
| （注册或设立所在地，?其它管辖区) （公司注册） |
（委员会文件编号） | 税务局雇主 |
(总部地址，包括邮政编码)
(
(注册人的电话号码，包括区号)
无数据
（自上次报告以来名称或地址发生变更，填写旧名称或地址）
根据证券法第12(b)条注册的证券：
| 每个类别的名称： | 交易标的 | 注册在每个交易所的名称： | ||
| 本基金寻求于东欧地区注册的主要权益关联发行人的长期升值投资。 | ||||
| 本基金寻求于东欧地区注册的主要权益关联发行人的长期升值投资。证券交易所 LLC |
根据《证券法》第425条规定的书面通信（17 CFR 230.425)
| 根据证券法规则425条（17 CFR 230.425）的书面 通信 |
| 根据交易所法规定14a-12条的招股材料(17 CFR 240.14a-12) |
| 根据交易所法规定14d-2(b)条的发起前通信(17 CFR 240.14d-2(b)) |
| 根据《交易所法》规则13e-4(c)进行的开篇通讯（17 CFR 240.13e-4(c)) |
请勾选表示注册人是否符合1933年证券法规定的新兴成长公司（第405条规则，本章第230.405条）或1934年证券交易法规定的规则1202亿.2（本章第2401亿.2条）。
新兴成长公司
如果作为新兴成长公司，标注检查标记表示注册人选择遵从根据《交易所法案》第13(a)条规定提供的任何新的或修订财务会计准则的延迟过渡期。
项目1.01.签订重大合同。
2024年8月27日，DatChat公司与Judaopta LLC（以下简称“卖方”），一家特拉华州有限责任公司，签署了一份资产购买协议，在此协议下，DatChat公司从卖方获得了以下资产：（i）某些软件（以下简称“RenAI软件”），这是一种用于媒体库组织的人工智能（AI）工具，具有使用AI标记和重命名PC和MAC设备图像的能力，并与Gemini、OpenAI和Claude集成功能，以及（ii）某些域名，作为交换条件，DatChat公司将8,000,000股受限制的Dragon Interact, Inc.普通股转让给卖方。
前述的采购协议摘要并不意味着是完整的描述，其全部内容均受附件10.1所附的采购协议的全文描述所限，并以此参考。
8.01其他事件。
2024年8月29日，公司发布新闻稿宣布购买协议和资产收购。新闻稿副本作为附件99.1附上，并通过引用纳入本文件。
项目9.01 基本报表和展示文件。
(d) 附件
| 展示编号 | 描述 | |
| 10.1#* | 2024年8月27日，DatChat，Inc.和Judaopta LLC.之间签订的资产购买协议。 | |
| 99.1 | 2024年8月29日的新闻发布。 | |
| 104 | 封面交互数据文件（嵌入在Inline XBRL文档中）。 |
| # | 根据S-K法规第601(b)(10)条，通过使用星号标记已将此展品的某些机密部分省略，因为经确认的机密部分(i)不重要，且(ii)如果公开披露会对竞争造成危害 |
| * | 本展品的时间表（以及类似附件）已根据《S-k法规》第601（b）（2）项的规定被省略。公司同意在证券交易委员会要求时提供任何被省略的时间表（或类似附件）的补充副本。 |
-1-
签名
根据《证券交易法》的规定，注册人已授权其代表签署本报告。
| DATCHAt，INC。 | ||
| Loss after tax for FY2024 was US$8800万, a 7% increase compared to US$8190万 for FY2023. The net loss attributable to ordinary shareholders was 8.91 US cents per share for FY2024, compared with 10.53 US cents per share for FY2023. Conference Call There will be a webcast today, beginning at 8.30am AESt (Thursday, August 29); 6.30pm EDt (Wednesday, August 28). It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late- stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, biologic-resistant inflammatory bowel disease, and acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast References / Footnotes 1. Jagasia m et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14; 135(20): 1739–1749 2. Abedin S, et al. Ruxolitinib resistance or intolerance in steroid-refractory acute graft versus-host disease — a real-world outcomes analysis. British Journal of Haematology, 2021;195:429–43. 3. Wittenberg RE, Gauvreau k, Leighton J, Moleon-Shea m, Borow Km, Marx GR, Emani Sm, Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndrome, JTCVS Open Volume 16, Dec 2023, doi: https://doi.org/10.1016/j.xjon.2023.09.031 4. Symons JD, Deeter L, Deeter N, et al. Effect of continuous-flow left ventricular assist device support on coronary artery endothelial function in ischemic and nonischemic cardiomyopathy. Cir Heart Fail 2019; 12:e006085. DOI: 10.1161/CIRCHEARTFAILURE.119.006085. 5. Using Reserve Bank of Australia (RBA) published exchange rate from June 30, 2024 of 1A$:0.6624US$. 6. TEMCELL® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd. 7. TEMCELL sales by our Licensee are recorded in Japanese Yen before being translated into USD for the purposes of calculating the royalty paid to Mesoblast. Results have been adjusted for the movement of the USD to Japanese Yen exchange rate from 1USD:140.01 Yen for the twelve months ended June 30, 2023 to 1USD:151.75 Yen for the twelve months ended June 30, 2024. Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our | 通过： | / s / Darin Myman |
| 姓名： | Darin Myman | |
| 标题： | 首席执行官 | |
-2-